Vychodoslovensky Onkologicky Ustav a.s.
- Address
- lock Available on a paid plan
Oncology and Solid Tumor Research at Vychodoslovensky Onkologicky Ustav a.s.
Clinical trials at this hospital-based research site focus mainly on neoplasms, with studies spanning cancers of the prostate, lung, breast, colorectal region, pancreas, biliary tract, melanoma, and head and neck. The research is centered on testing new treatment options and improving outcomes for patients with advanced or hard-to-treat cancers.
- Prostate cancer studies exploring better control of localized, recurrent, and metastatic disease
- Breast cancer research in hormone receptor-positive and HER2-negative advanced disease
- Lung and thoracic cancer trials evaluating new approaches for non-small cell lung cancer
- Colorectal, pancreatic, biliary tract, melanoma, and head and neck cancer investigations
The site’s clinical trials department supports research aimed at assessing treatment effectiveness, extending survival, and refining cancer care for patients across several difficult-to-treat tumor types.
Prostate Cancer and Genitourinary Oncology
A major part of the research portfolio addresses prostate cancer, including high-risk localized disease, recurrent disease, and castration-sensitive or castration-resistant metastatic forms. These studies are designed to improve disease control and delay progression using new combinations of hormonal and targeted treatments.
- Localized and locally advanced high-risk prostate cancer
- Metastatic castration-sensitive prostate cancer
- Metastatic castration-resistant prostate cancer
- Recurrent or high-risk prostate cancer after definitive treatment
Research here also includes work on androgen receptor–related therapies and other strategies intended to strengthen long-term cancer control while monitoring safety and quality of life.
Breast Cancer and Hormone-Driven Tumor Studies
The site is actively involved in trials for advanced breast cancer, especially hormone receptor-positive and HER2-negative disease. These studies look at whether newer treatment combinations can better slow cancer growth after prior therapy.
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
- Estrogen receptor-positive advanced breast cancer
- Metastatic breast cancer with molecular features linked to treatment resistance
This research reflects a strong interest in precision oncology, with the goal of matching treatment more closely to tumor biology and improving progression-free survival.
Digestive System and Colorectal Cancer Research
Several trials at the site focus on colorectal cancer and other gastrointestinal malignancies, including metastatic disease and genetically defined subgroups. The main purpose is to test new treatment approaches that may improve disease control for patients with limited standard options.
- Metastatic colorectal cancer, including BRAF- and KRAS-driven disease
- Untreated metastatic pancreatic ductal adenocarcinoma
- Advanced HER2-expressing biliary tract cancer
These studies combine interest in targeted therapy, immunotherapy, and broader treatment optimization for advanced digestive tract cancers.
Lung Cancer and Thoracic Malignancy Trials
Another important research area is non-small cell lung cancer, including metastatic disease and tumors with specific molecular changes such as ROS1 rearrangements or KRAS G12C mutations. The trials are aimed at improving treatment effectiveness and exploring more personalized options for patients with advanced disease.
- Metastatic non-small cell lung cancer
- ROS1-rearranged non-small cell lung cancer
- KRAS G12C-mutant non-small cell lung cancer
- Stage II to IIIB non-small cell lung cancer after surgery or in locally advanced settings
Work in this field also includes studies of immunotherapy and targeted treatment combinations to help delay progression and improve survival outcomes.
Other Oncology and Supportive Care Research
In addition to tumor-directed studies, the site conducts research in broader areas such as cancer cachexia and other conditions linked to advanced malignancy. These trials aim to improve symptoms, body weight, and overall well-being for people living with cancer.
- Cancer cachexia and weight loss in advanced cancer
- Supportive care research for fatigue and appetite-related symptoms
- Studies where the disease area is not narrowly specified but remains oncology-focused
This work complements the cancer treatment portfolio by addressing quality of life and symptom management alongside anti-cancer therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Pfizer Inc.4active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.11trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vychodoslovensky Onkologicky Ustav a.s.
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3) | Pfizer Inc. | Phase III | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2021-09-16 | 2025-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.